· 3 min read

🎻 The Propranolol Concert

27% of elite orchestra musicians secretly take heart medication before performances. Not to play better — just to stop their bodies from sabotaging the show. That "tax on being nervous" is now a wide-open market.

🎻 The Propranolol Concert

In 1987, the International Conference of Symphony and Opera Musicians surveyed professional orchestra players about performance anxiety. Twenty-seven percent admitted to using beta-blockers before auditions and concerts. The real number was almost certainly higher, because admitting you need chemical help to play Brahms carries its own stigma.

These weren't amateurs. They were world-class musicians who'd trained for decades. But the body doesn't care about your résumé.

Propranolol, a blood pressure pill invented in the 1960s, became classical music's worst-kept secret. It didn't make anyone play better. It just stopped the body from hijacking the performance. Musicians who've talked about it describe the effect the same way: it removes the tax on being nervous.

Most people don't fail because they're unprepared. They fail because their body charges a toll their mind already paid. The problem was never skill. It was the tax.

That tax is a market.

Millions of people — founders pitching VCs, salespeople on quarterly calls, brides giving toasts, coders presenting at demo day — are quietly Googling "how to stop shaking during presentation" the night before. They won't bring it up with their doctor because it feels too weird and too small for a real appointment.

Hims & Hers figured this out. They built a $2.3 billion business on the insight that privacy is a product category. But they're chasing the giant conditions — weight loss, hair, ED.

The long tail of small, episodic, shame-adjacent problems? Wide open.

The play: a "shadow health router" — one async telehealth front door for the stuff people won't tell their PCP. Performance anxiety first. Event-driven hyperhidrosis second. Each micro-brand feeds a shared clinical engine, shared retention logic, and a compounding moat. Early unit economics suggest $45–75 per protocol with membership upsides pushing LTV significantly higher, on infrastructure that already exists.

Read the full playbook here:

Async telehealth infrastructure is mature, Hims proved privacy-seeking behavior converts at scale, but episodic stigmatized symptoms remain fragmented and underserved.

Full Playbook

From the Vault:

Component scarcity became structural in 2025, creating sustained premiums for brokers who verify surplus inventory and operationalize export compliance workflows.

Full Playbook

OpenAI's Prism standardized ML research authoring. The next layer is distribution—turning papers into model cards, demos, and landing pages researchers already need.

Full Playbook

Policy chaos and AI-era equity wealth are minting thousands of founders who need tax planning tools that don't exist yet.

Full Playbook

Read next

🧵 Yes, Needlepoint

🧵 Yes, Needlepoint

Vinyl outsold CDs. Instax hit 100M cameras. LEGO built a $679 set for adults. The nostalgia premium is real — and it just landed on needlepoint. Searches are up 172%. Nobody has built the tool the new buyer actually needs.

Startup Heist | Briefings
Startup Heist | Briefings
· 3 min read
🔗 Chanel's Timestamp

🔗 Chanel's Timestamp

Coco Chanel named the 2.55 after the month and year she finished it. Birth-year buyers in 2026 want the same thing — and no marketplace is built for that search. Here's the $20K–$40K MRR play hiding in luxury resale.

Startup Heist | Briefings
Startup Heist | Briefings
· 3 min read
New startup opportunities, ideas and insights right in your inbox.